Visual worsening was neither associated with the treatment group nor with the papilledema degree or visual impairment at baseline (Supplementary Table 4)
Mixed results may also reflect the fact that intranasal oxytocin may not be able to reach the oxytocin neurons involved in social behavior, experts say
Gregory Lubiniecki, vice president of oncology clinical research at Merck Research Laboratories, noted in a statement that prognoses are generally poor for this disease and said the company is pleased to offer a new first-line treatment option. The approval was backed by results from the Phase II/III KEYNOTE-483 trial, where Keytruda elicited a significant survival benefit for patients, cutting the risk of death by 21%
Even with new breakthroughs, the company's top-line growth will eventually slow as new launches erode some of its pricing power
GLP-1 receptor agonists like semaglutide trigger a chain of biological events that suppress hunger signals and improve metabolic control
Published clinical studies report that intranasal Semax is well tolerated by test subjects and does not cause notable side effects
